File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network

TitlePomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
Authors
Issue Date2019
PublisherNature Publishing Group: Open Access Journals. The Journal's web site is located at http://www.nature.com/bcj/index.html
Citation
Blood Cancer Journal, 2019, v. 9, p. article no. 83 How to Cite?
AbstractPomalidomide is a third generation immunomodulatory drug which in combination with dexamethasone, has been shown to be active in relapsed/refractory multiple myeloma. However, the data in Asian patients remain limited. We conducted a prospective phase two clinical trial in major cancer centers in Singapore, South Korea, Taiwan, Japan and Hong Kong to assess the efficacy and safety of pomalidomide and dexamethasone combination (PomDex) +/− cyclophosphamide in Asian patients with relapsed/refractory multiple myeloma who failed lenalidomide and bortezomib. Patients were treated with pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly). If there is less than a minimal response after three cycles of PomDex, cyclophosphamide 300 mg/m2 can be added (PomCyDex). A total of 136 patients were enrolled. The median PFS was 9 and 10.8 months for the PomDex and PomCyDex group, respectively. The median OS was 16.3 months. This regimen appears to be active across age groups and prior lines of treatment. This combination was overall well tolerated with grade 3 and 4 adverse events of mainly cytopenias. PomDex is highly active and well-tolerated in Asian patients. The addition of cyclophosphamide can improve the response and outcomes further in patients with suboptimal response to PomDex.
Persistent Identifierhttp://hdl.handle.net/10722/307894
ISSN
2023 Impact Factor: 12.9
2023 SCImago Journal Rankings: 3.974
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSoekojo, CY-
dc.contributor.authorKim, K-
dc.contributor.authorHuang, SY-
dc.contributor.authorChim, CS-
dc.contributor.authorTakezako, N-
dc.contributor.authorAsaoku, H-
dc.contributor.authorKimura, H-
dc.contributor.authorKosugi, H-
dc.contributor.authorSakamoto, J-
dc.contributor.authorGopalakrishnan, SK-
dc.contributor.authorNagarajan, C-
dc.contributor.authorWei, Y-
dc.contributor.authorMoorakonda, R-
dc.contributor.authorLee, SL-
dc.contributor.authorLee, JJ-
dc.contributor.authorYoon, SS-
dc.contributor.authorKim, JS-
dc.contributor.authorMin, CK-
dc.contributor.authorLee, JH-
dc.contributor.authorDurie, B-
dc.contributor.authorChng, WJ-
dc.date.accessioned2021-11-12T13:39:27Z-
dc.date.available2021-11-12T13:39:27Z-
dc.date.issued2019-
dc.identifier.citationBlood Cancer Journal, 2019, v. 9, p. article no. 83-
dc.identifier.issn2044-5385-
dc.identifier.urihttp://hdl.handle.net/10722/307894-
dc.description.abstractPomalidomide is a third generation immunomodulatory drug which in combination with dexamethasone, has been shown to be active in relapsed/refractory multiple myeloma. However, the data in Asian patients remain limited. We conducted a prospective phase two clinical trial in major cancer centers in Singapore, South Korea, Taiwan, Japan and Hong Kong to assess the efficacy and safety of pomalidomide and dexamethasone combination (PomDex) +/− cyclophosphamide in Asian patients with relapsed/refractory multiple myeloma who failed lenalidomide and bortezomib. Patients were treated with pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly). If there is less than a minimal response after three cycles of PomDex, cyclophosphamide 300 mg/m2 can be added (PomCyDex). A total of 136 patients were enrolled. The median PFS was 9 and 10.8 months for the PomDex and PomCyDex group, respectively. The median OS was 16.3 months. This regimen appears to be active across age groups and prior lines of treatment. This combination was overall well tolerated with grade 3 and 4 adverse events of mainly cytopenias. PomDex is highly active and well-tolerated in Asian patients. The addition of cyclophosphamide can improve the response and outcomes further in patients with suboptimal response to PomDex.-
dc.languageeng-
dc.publisherNature Publishing Group: Open Access Journals. The Journal's web site is located at http://www.nature.com/bcj/index.html-
dc.relation.ispartofBlood Cancer Journal-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titlePomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network-
dc.typeArticle-
dc.identifier.emailChim, CS: jcschim@HKUCC-COM.hku.hk-
dc.identifier.authorityChim, CS=rp00408-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1038/s41408-019-0245-1-
dc.identifier.pmid31594919-
dc.identifier.pmcidPMC6783445-
dc.identifier.scopuseid_2-s2.0-85073056680-
dc.identifier.hkuros329789-
dc.identifier.volume9-
dc.identifier.spagearticle no. 83-
dc.identifier.epagearticle no. 83-
dc.identifier.isiWOS:000489962300001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats